Tine Rosenberg1,2, Bahareh B Philipsen1,2, Camilla S Mehlum1,2, Anne-Kirstine Dyrvig3, Sonja Wehberg4, Magdalena Chirilǎ5, Christian Godballe1,2. 1. Department of ORL-Head & Neck Surgery and Audiology, Odense University Hospital, Odense. 2. Department of Clinical Research, Department of Public Health, University of Southern Denmark, Odense. 3. Research Unit for General Practice, Department of Public Health, University of Southern Denmark, Odense. 4. Department for Database Section 1: Cardiovascular, Surgical and Acute Domains, Danish Clinical Registries, Odense. 5. Otorhinolaryngology Department, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Romania.
Abstract
BACKGROUND: Recurrent respiratory papillomatosis is a benign condition caused by human papillomavirus (HPV). Surgery is the mainstay of treatment, but numerous adjuvant therapies have been applied to improve surgical outcome. Recently, HPV vaccination has been introduced, but only smaller studies of its effect have been published. The present meta-analysis is intended as a possible substitute for a proposed but not yet realized multicenter randomized controlled trial. METHODS: A systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement. PubMed, Embase, and Cochrane were systematically searched. All retrieved studies (n = 593) were reviewed and qualitatively assessed. In addition, 2 previously unpublished data sets were included. The systematic review included 11 studies, comprising 133 patients, of whom 63 patients from 5 studies were eligible for meta-analysis. A random-effects meta-analysis was conducted for the mean difference in number of surgical procedures per month before and after vaccination. RESULTS: The number of surgical procedures per month was significantly reduced after HPV vaccination compared with before vaccination (estimated mean, 0.06 vs 0.35). The mean intersurgical interval increased from 7.02 months (range, 0.30-45 months) before to 34.45 months (2.71-82 months) after HPV vaccination. CONCLUSION: The present study supports the continued use of the HPV vaccine as an adjuvant treatment for recurrent respiratory papillomatosis.
BACKGROUND: Recurrent respiratory papillomatosis is a benign condition caused by human papillomavirus (HPV). Surgery is the mainstay of treatment, but numerous adjuvant therapies have been applied to improve surgical outcome. Recently, HPV vaccination has been introduced, but only smaller studies of its effect have been published. The present meta-analysis is intended as a possible substitute for a proposed but not yet realized multicenter randomized controlled trial. METHODS: A systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement. PubMed, Embase, and Cochrane were systematically searched. All retrieved studies (n = 593) were reviewed and qualitatively assessed. In addition, 2 previously unpublished data sets were included. The systematic review included 11 studies, comprising 133 patients, of whom 63 patients from 5 studies were eligible for meta-analysis. A random-effects meta-analysis was conducted for the mean difference in number of surgical procedures per month before and after vaccination. RESULTS: The number of surgical procedures per month was significantly reduced after HPV vaccination compared with before vaccination (estimated mean, 0.06 vs 0.35). The mean intersurgical interval increased from 7.02 months (range, 0.30-45 months) before to 34.45 months (2.71-82 months) after HPV vaccination. CONCLUSION: The present study supports the continued use of the HPV vaccine as an adjuvant treatment for recurrent respiratory papillomatosis.
Authors: Jana Smahelova; Eva Hamsikova; Viera Ludvikova; Jitka Vydrova; Joseph Traboulsi; Ondrej Vencalek; Petr Lukeš; Ruth Tachezy Journal: JAMA Otolaryngol Head Neck Surg Date: 2022-07-01 Impact factor: 8.961
Authors: Raiza Amiling; Elissa Meites; Troy D Querec; Laura Stone; Vidisha Singh; Elizabeth R Unger; Craig S Derkay; Lauri E Markowitz Journal: J Pediatric Infect Dis Soc Date: 2021-08-17 Impact factor: 5.235
Authors: R L O van de Laar; W Hofhuis; R G Duijnhoven; S Polinder; W J G Melchers; F J van Kemenade; R L M Bekkers; H J Van Beekhuizen Journal: BMC Cancer Date: 2020-06-09 Impact factor: 4.430